Kymera Therapeutics Inc. (KYMR)
NASDAQ: KYMR
· Real-Time Price · USD
43.03
13.39 (45.18%)
At close: Jun 02, 2025, 3:59 PM
43.33
0.70%
After-hours: Jun 02, 2025, 07:58 PM EDT
45.18% (1D)
| Bid | 42.97 |
| Market Cap | 2.8B |
| Revenue (ttm) | 58.88M |
| Net Income (ttm) | -240.88M |
| EPS (ttm) | -3.11 |
| PE Ratio (ttm) | -13.84 |
| Forward PE | -7.56 |
| Analyst | Buy |
| Ask | 43.33 |
| Volume | 6,029,551 |
| Avg. Volume (20D) | 717,206 |
| Open | 40.00 |
| Previous Close | 29.64 |
| Day's Range | 36.86 - 43.97 |
| 52-Week Range | 19.45 - 53.27 |
| Beta | 2.19 |
About KYMR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol KYMR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for KYMR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 day ago
+45.51%
Kymera Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
4 months ago
+7.61%
Kymera Therapeutics shares are trading higher. Stephens & Co. reiterated an Overweight rating on the stock.
2 weeks ago · seekingalpha.com
Kymera Therapeutics: Intriguing Degradation Thesis, But A Bit Powder PuffI'm downgrading Kymera to 'Hold' due to slow clinical progress, pipeline uncertainty, and lack of near-term catalysts despite strong cash position. Kymera's unique focus on immunology with oral protei...
3 weeks ago · seekingalpha.com
Kymera Therapeutics, Inc. (KYMR) Q1 2025 Earnings Call TranscriptKymera Therapeutics, Inc. (NASDAQ:KYMR ) Q1 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Justine Koenigsberg - Vice President of Investor Relations Nello Mainolfi - Found...
